Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching from IR Seroquel to SR Seroquel in Outpatients with Schizophrenia

Study identifier:D1444C00146

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

6-week Multicenter, Double-blind, Randomized, Parallel-group, Phase 3 Study to Evaluate the Feasibility of Switching from Immediate-release Quetiapine Fumarate (SEROQUEL) to Sustained-release Quetiapine Fumarate in Outpatients with Schizophrenia (abbreviated)

Medical condition

schizophrenia

Phase

Phase 3

Healthy volunteers

No

Study drug

Seroquel SR

Sex

All

Actual Enrollment

454

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Nov 2004
Primary Completion Date: 01 Feb 2006
Study Completion Date: 01 Feb 2006

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria